Page 11 - Tanmay Tiwary

HDFC Bank gets 'Buy' again from Nomura, target price tweaked; here's why

Nomura noted that HDFC Bank is well-positioned to sustain credit growth at system levels or slightly higher through FY26.

Top 3 reasons why Emkay is upbeat on Vishal Mega Mart; initiates with 'Buy'

Vishal Mega Mart's growth is less capital-intensive, with a sizable portion coming from SSG, Emkay analysts noted.

Marico eyes 30% Q2 revenue surge on price hikes; margin pressure temporary

Marico's India volumes are projected to grow 7 per cent Y-o-Y, while domestic pricing gains are estimated at 26 per cent.

Metro Brands' growth promises hit by stretched valuations, say analysts

HDFC Securities, in a note dated September 30, maintained its 'Sell' recommendation, due to expensive valuations at 55x estimated September 2027 P/E.

Amara Raja: Analysts keep Buy on strong LAB, margin gains and lithium push

For FY26, Amara Raja has planned ₹1,200 crore in capex, split into ₹800 crore for lithium and ₹400 crore for LAB.

CAMS, Nuvama, ABSL AMC: Why is Motilal Oswal betting on these stocks?

According to Motilal Oswal, retail mutual fund activity has shown some moderation, particularly in Systematic Investment Plan (SIP) flows, as one-year SIP returns have turned negative.

Jefferies says 'Buy' Amber, Syrma, 'Hold' Dixon amid PCB expansion plans

Amber and Syrma are primarily targeting printed circuit board (PCB) manufacturing, while Dixon is focused on backward integration in mobile value chains, specifically camera and display modules.

Analysts see up to 34% upside in ACME Solar Holdings stock; here's why

ACME Solarcontinues to actively bid for utility-scale projects, and incremental awards are essential for building earnings visibility into FY29 and beyond.

Nuvama increases Bajaj Consumer target to ₹307 on GST boost, growth revival

Nuvama maintained a 'Buy' rating, underpinned by expectations of a revival in consumption and strategic focus on core categories.

IndiGo: Analysts advise 'Hold' despite rich valuations, sector headwinds

Nuvama flagged 'high valuations' and 'near-term industry weakness' as key reasons for caution, even as structural positives remain intact.

September quarter set for GST hiccups, analysts back HUL, Britannia, Marico

Heavy rains in Q2FY26 adversely affected seasonal categories such as carbonated drinks, ready-to-drink juices, beer, ice creams, and hair/skin summer care products.

Cement prices to remain weak in coming qtrs despite demand: Elara Capital

Elara Capital cautions that the near-term pricing environment remains weak, with operating leverage and higher costs likely to weigh on profitability in Q2FY26 and potentially spill over into Q3FY26.

Why Motilal Oswal retained 'Buy' on Bharat Electronics; shares up 3%

Motilal Oswal analysts retained their 'Buy' rating on BEL with a target price of ₹490, based on 45 times September 2027 estimated earnings.

Analysts hike Jindal Steel target price; 4 key triggers behind the upgrade

Analysts at Nuvama have revised their target price on the Jindal Steel stock to ₹1,426 from ₹1,193 earlier, valuing it at 7x FY28E EV/Ebitda, and reiterated a 'Buy' rating.

Auto sales set for strong September; analysts bet on Maruti, M&M, TVS Motor

September auto sales expectations: Analysts cite the start of festive sales from September 22, improved finance availability, dealer inventory build-up, and positive rural sentiment as key drivers.

InCred Equities retains 'Reduce' on Hyundai, lifts target; GST gain limited

The brokerage highlighted that while the recent Goods and Services Tax (GST) rate cut could provide some relief to the auto sector, its benefit for Hyundai's revenue is limited.

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Analysts see strong boost to HAL's orderbook after MoD orders 97 Tejas jets

Nomura maintains a 'Buy' rating on HAL with a target price of ₹6,100, citing the streamlined delivery process and the bolstered order book as key positives.

Titan gets Nomura 'Buy' call on strong jewellery market, 27% upside eyed

Analysts at Nomura have initiated coverage of Titan with a 'Buy' rating and a target price of ₹4,275, highlighting the company's strong positioning relative to peers on a risk-weighted basis.

Why Nomura continues to back Glenmark Pharma; Retains 'Buy'; Find out here

Analysts at Nomura continue to back Glenmark Pharma, citing the company's ability to strategically acquire high-potential innovative products.